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tress-related psychiatric disorders such as anx-
iety and major depression impair the lives of approxi-
mately 10% to 15% of the population. For many years,
the success of the pharmacological treatment of these
disorders has been restrained by various factors,includ-
ing long latency of clinical effect, treatment resistance,
adverse side effects, and, in the case of the anxiolytic
benzodiazepines, tolerance and addictive potential.
Although stress has continuously been a subject of
research since the 1940s, the pharmacological principle
of action (ie,the interaction with the classic neurotrans-
mitters such as serotonin, noradrenaline, and 
γ-aminobutyric acid [GABA]) of the antidepressant and
anxiolytic drugs prescribed today still stems from work
carried out as early as the 1950s.
A new epoch began in 1981 with the discovery of corti-
cotropin-releasing hormone (CRH) as the principal
mediator of the effects of stress on the hypothalamic-
pituitary-adrenocortical (HPA) axis and behavior.
1 Not
surprisingly,clinical studies soon demonstrated that this
neuropeptide is implicated in depression and anxiety
disorders.
2-5 Moreover, basic research studies have pre-
sented evidence that elevated central CRH levels are
involved in the etiology of stress-related physiological
and behavioral disorders.
6 In pharmacology, however,
the discovery of two types of CRH-binding receptors
(CRHR1 and CRHR2) and a nonreceptor CRH-bind-
ing protein (CRHBP) was an immense breakthrough.
With the recent discovery of more—endogenous—lig-
ands beside CRH,the concept is dawning that CRH,its
congeners,and their receptors form an intricate network
in the brain,which provides a variety of potential targets
for drug intervention.
Here, we review recent developments regarding the
functions of CRHR1, CRHR2, and their ligands in the
brain. On the basis of the new reported findings, we 
put forward a new concept of the role of CRHR1,
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On the basis of extensive basic and clinical studies, corti-
cotropin-releasing hormone (CRH) and its related family
members are considered to play a pivotal role in stress-
related disorders, such as anxiety and depression. CRH is
regarded as the principal mediator in the brain of the
stress response, as it mediates neuroendocrine, auto-
nomic, and behavioral responses to stressful challenges.
Recently, this neuropeptide family has expanded due to
the discovery of two new members, urocortin II (also
termed stresscopin-related peptide) and urocortin III (also
termed stresscopin), which are selective agonists for the
CRH receptor type 2. They show a discrete neu-
roanatomical localization and are involved in stress-cop-
ing responses, such as anxiolysis. Here, on the basis of
recent developments, we suggest that CRH, the uro-
cortins, and their receptors form a complex system in
the brain, which is recruited during both the acute and
the recovery phases of the stress response.
S
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ery phases of the stress response.This concept is also
presented as a hypothetical model for the pathophysiol-
ogy of anxiety and major depressive disorders.
The expanding family of CRH 
and its receptors
The number of known members of the CRH family of
neuropeptides has considerably grown during recent
years. Until recently, it also comprised peptides struc-
turally related to CRH,including urocortin (Ucn),
7 fish
urotensin I,
8 and amphibian sauvagine.
9 The biological
actions of CRH and Ucn are mediated via binding to
two types of G-protein–coupled receptors,CRHR1 and
CRHR2, which have different expression patterns and
physiological functions.
10-12 Regarding CRHR2, two dif-
ferent splice variants were identified, CRHR2α and
CRHR2β, which have an uneven distribution between
brain (CRHR2α) and periphery (CRHR2β) in rodents.
13
CRHR1 binds both CRH and Ucn with high affinity,
whereas CRHR2 shows a clear preference for Ucn
(Table I).
10,11,14,15 The next question was whether a neu-
ropeptide that selectively binds to CRHR2 exists in
mammalian brain.
This question was answered by the very recent discov-
ery of two selective ligands for CRHR2, Ucn II (also
termed stresscopin-related peptide
16,17) and Ucn III (also
called stresscopin
14,17) using mouse and human cDNA
libraries (Table I).In contrast to CRH and Ucn,neither
Ucn II nor Ucn III bind to CRHBP.
14The murine Ucn II
(mUcn II) gene encodes a 112–amino acid (aa) precur-
sor containing a putative 38-aa mature peptide at the C
terminus.
16 Amino acid sequences in the coding region
of mUcn II show 76%, 47%, 34%, and 42% homology
with human urocortin-related peptide (URP [GenBank
accession No. BE622276], which Lewis et al
14 proposed
should be called hUcn II;henceforth this nomenclature
is adopted in this paper), pufferfish (Takifugu rubripes)
URP,
18 human/rat CRH (h/rCRH),and rat Ucn (rUcn),
respectively.The putative 38-aa sequence of hUcn III
and mUcn III share 40% and 37% sequence homology
with mUcn II and hUcn II, respectively.
14 Their rather
distant relationship with CRH and Ucn is illustrated by
their modest homology with h/rCRH (32% and 26%)
and hUcn and mUcn (21% and 18%). hUcn III and
mUcn III share an identity of 42% and 37% with hUcn
II and mUcn, whereas, out of three pufferfish peptide
sequences,two (GenBank accession Nos.AJ251323 and
AL175143) were highly related to hUcn III and mUcn
III, and the third one resembled mostly fish (eg, floun-
der) urotensin I.
14
Thus, in mammalian brain, the CRH/Ucn receptor net-
work comprises two receptor types and four ligands, of
which three (CRH,Ucn II,and Ucn III) are pharmaco-
logically monogamous and one (Ucn) is,at least regard-
ing CRHR1 and CRHR2,promiscuous.The complexity
is further increased by the presence of a binding protein,
which presumably constrains the biological activity of
CRH and Ucn.
19
CRHR1 and CRHR2 in the brain: receptor vs
ligand distribution
CRHR1 and CRHR2 mRNA show a distinct,but over-
lapping, distribution in the brain as revealed by in situ
hybridization histochemistry studies (Figure 1A).
12,20-23
CRHR1 displays a widespread distribution in the cen-
tral nervous system (CNS) regions involved in sensory
information processing and motor control, such as the
cortical mantle, olfactory bulb and related regions, hip-
pocampus, amygdala (mainly basolateral, medial, and
cortical nuclei), basal ganglia, certain thalamic nuclei,
Basic research
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Selected abbreviations and acronyms
ACTH adrenocorticotropic hormone
BNST bed nucleus of the stria terminalis
CREB cAMP response element–binding protein
CRH corticotropin-releasing hormone 
CRHR CRH-binding receptor
ERPs event-related potentials
EW Edinger-Westphal nucleus
GR glucocorticoid receptor
HPA hypothalamic-pituitary-adrenocortical (axis)
ICV intracerebroventricular
iLS intermediate lateral septal nucleus
ir immunoreactive
LS lateral septum 
MR mineralocorticoid receptor
NTS nucleus tractus solitarius
ODN oligodeoxynucleotide
PVH hypothalamic paraventricular nucleus
Ucn urocortin
VMH ventromedial hypothalamic nucleusmedial and lateral hypothalamic nuclei, periaqueductal
gray area, many brainstem nuclei (sensory, motor, and
reticular), and cerebellum (Figure 1A). In contrast,
CRHR2 is virtually restricted to subcortical structures
such as the lateral septum (LS),bed nucleus of the stria
terminalis (BNST), the ventromedial hypothalamic
nucleus (VMH),and certain amygdaloid nuclei (medial
and cortical nuclei). Moderate levels of both receptors
are expressed in the dorsal and median raphe nuclei,
whereas only low levels are found in the hypothalamic
paraventricular nucleus (PVH).
12,20-22 In the anterior pitu-
itary, CRHR1 mediates the effects of CRH on adreno-
corticotropic hormone (ACTH) release and, thus, on
glucocorticoid hormone secretion (Figure 1A).
10,22
Due to its pharmacologically characterized effects in the
brain in terms of autonomic, neuroendocrine, behav-
ioral, and emotional changes,
24 CRH is regarded as the
principal mediator of the stress response. However, as
pointed out by Bittencourt and Sawchenko,
21 a puzzling
issue remains that neuronal activation (in terms of Fos
expression) is found in nuclei known to be pertinent for
eliciting the stress response (eg, the central nucleus of
the amygdala, paraventricular nucleus, nucleus tractus
solitarius (NTS),ventrolateral medulla,locus ceruleus),
but not containing appreciable amounts of either
CRHR mRNA expression
12,23 or CRH binding.
25 A pos-
sible explanation may be the occurrence of transsynap-
tic effects via structures that do contain CRHR1 or
CRHR2, but this notion can only be partly satisfactory
given the multitude and potency of CRH-induced
responses.
A mismatch has been found with regard to the localiza-
tion of Ucn-immunoreactive (ir) fibers and CRHR2 dis-
tribution. Brain nuclei expressing highest levels of Ucn
mRNA, ie, the Edinger-Westphal nucleus (EW), the lat-
eral olivary nucleus, and the supraoptic nucleus (Figure
1B),mainly project caudally;this is in the face of high con-
centrations of CRHR2 in forebrain areas, such as the
BNST, LS, and VMH.
20 However, a Ucn-ir projection
stemming from the EW was found terminating in the
intermediate lateral septal nucleus (iLS),
21 but the projec-
tion ended in a region medially localized from the ventro-
lateral part to which CRHR2 is confined.
20With the recent
discovery of the CRHR2-selective ligands Ucn II and Ucn
III,the issue regarding the localization of the endogenous
ligands of forebrain CRHR2 can be addressed.
The distribution of Ucn II mRNA is distinctly subcorti-
cal, including regions known to be involved in physio-
logical and behavioral responses to stress, such as the
PVH (HPA axis and autonomic control
26), the locus
ceruleus (arousal and anxiety
27), and the arcuate nucle-
us (food intake and energy balance
28),and is partly over-
lapping that of CRH (PVH
29) and Ucn (brainstem and
spinal motor nuclei) (Figure 1B).
20 Intracerebroventric-
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Table I. Binding properties and functional activities of members of the corticotropin-releasing hormone (CRH) neuropeptide family.
Data are extracted from references 10, 11, 14, and 15. Values were determined using transiently transfected COS-M6 cells (h/rCRH only), tran-
siently or stably transfected mouse Ltk- cells (h/rCRH only), or stably transfected Chinese hamster ovary cells (cAMP measurements) or their
membranes (binding experiments). *Binding experiments were conducted with α- and β-splice variant of the human CRHR2. For more details,
see the mentioned publications. (-), data not available.
Ucn, urocortin; CRHR, corticotropin-releasing hormone receptor; h, human; m, murine; r, rat; Ki, dissociation constant; EC50, median effective
concentration.
Peptide Binding Binding Binding cAMP hCRHR1 cAMP rCRHR2α cAMP mCRHR2β
hCRHR1 rCRHR2α mCRHR2β (EC50, nM) (EC50, nM) (EC50, nM)
(Ki, nM) (Ki, nM) (Ki, nM)
CRH (rat/human) 3.3 42 47 4 20 -
CRH (sheep) 1.1 230* 320* - - -
Ucn (rat) 0.32 2.2 0.62 0.15 0.063 0.087
Ucn (human) 0.4 0.3* 0.5* - - -
Ucn II (human) >100 1.7 0.50 >100 0.26 0.42
Ucn II (mouse) >100 2.1 0.66 >100 0.14 0.05
Ucn III (human) >100 21.7 13.5 >100 0.16 0.12
Ucn III (mouse) >100 5.0 1.8 >100 0.073 0.081
Urotensin I (fish) 0.4 1.8* 5.7* - - -
Sauvagine (frog) 0.7 0.5* 2.1* - - -Basic research
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Figure 1. Distribution of CRHR1 and CRHR2 mRNA (A), and Ucn, Ucn II, and Ucn III mRNA (B) in a sagittal section of the rodent brain. The presented
mRNA distribution is based on in situ hybridization studies.
12,14,16,20-23 The drawn sagittal sections are only 2D schematic representations and,
therefore, cannot be neuroanatomically exact. Abbreviations: 7, facial nucleus; 12, hypoglossal nucleus; Amb, ambiguus nucleus; AON, ante-
rior olfactory nucleus; AP, area postrema; APit, anterior pituitary; ARC, arcuate nucleus; Basal G, basal ganglia; BLA, basolateral amygdala;
BNST, bed nucleus stria terminalis; CA1-3, fields CA1-3 of Ammon horn; CC, corpus callosum; CeA, central amygdaloid nucleus; Cereb, cere-
bellum; CingCx, cingulate cortex; CoA, cortical nucleus amygdala; Deep N, deep nuclei; DG, dentate gyrus; DBB, diagonal band of Broca; EW,
Edinger-Westphal nucleus; FrCx, frontal cortex; IC, inferior colliculi; IO, inferior olive; IPit, intermediate lobe of the pituitary; LC, locus ceruleus;
LDTg, laterodorsal tegmental nucleus; LS, lateral septum; LSO, lateral superior olive; MA, medial nucleus amygdala; MePO, median preoptic
area; MS, medial septum; NTS, nucleus tractus solitarius; OB, olfactory bulb; OccCx, occipital cortex; PAG, periaqueductal gray area; ParCx,
parietal cortex; PFA, perifornical area; PG, pontine gray, PPit, posterior pituitary; PPTg, pedunculopontine tegmental nucleus; PVH, paraven-
tricular hypothalamus; R, red nucleus; RN, raphe nuclei; SC, superior colliculi; SN, substantia nigra; SON, supraoptic nucleus; SP5n: spinal
trigeminal nucleus; SPO: superior paraolivary nucleus; Thal, thalamus; VMH, ventromedial hypothalamic nucleus.
A. CRHRI and CRHR2 mRNA distribution in the rodent brain and pituitary
B. Ucn, Ucn II, and Ucn III mRNA distribution in the rodent brain and pituitaryular (ICV) injection of Ucn II induces Fos expression in
the BNST, PVH, central nucleus of the amygdala,
parabrachial nucleus, and NTS, but not in other
CRHR2-rich locations,such as the LS,raphe nuclei,and
VMH.
16 In view of the high affinity of Ucn II for
CRHR2, the latter observation was unexpected and a
solid explanation is still lacking.The disagreement may
indicate the requirement of additional factors necessary
for activation of the neuron, at least in terms of Fos.
Alternatively, these CRHR2-expressing neurons may
display activation of signal transduction pathways not
ultimately leading to synthesis of Fos. For instance, we
have recently found that phosphorylation of cAMP
response element–binding protein (CREB),a transcrip-
tion factor activated through CRHR1 and CRHR2, is
not necessarily correlated with Fos expression (Bilang-
Bleuel et al, unpublished data). Nevertheless, given the
evident similarity between the localizations of Ucn II
and CRH,it seems pertinent that Ucn II participates in
responses to stress.
16 However,their differential binding
preference for CRHR1 and CRHR2 suggests that CRH
and Ucn II have different functions in the stress
response.
The localization of Ucn III (Figure 1B)
14,17 in the brain is
different from that of CRH,
29 Ucn,
20 and Ucn II.
16 This
latest discovered member of the CRH neuropeptide
family is found in the median preoptic area, the rostral
perifornical area (a region lateral from the PVN in the
hypothalamus),the posterior part of the BNST,and the
medial nucleus of the amygdala (Figure 1B).
14 Until now,
unfortunately, no Fos studies have been published with
Ucn III. It is relevant to note though that parts of the
perifornical region project into the (CRHR2-rich) LS,
an area in which both Ucn-ir and piscine urotensin I-ir
can be found.
20 However, within the LS, Ucn-ir and
urotensin I are differentially localized with Ucn-ir pre-
vailing in the medial aspect of the iLS and urotensin 
I-ir concentrating in the ventrolateral aspect of this
nucleus,ie,the site where CRH-R2 mRNA is also found
(see also above). It may be speculated that, given the
structural relationship between urocortins and
urotensin, the immunoreactivity in the ventrolateral
aspect of the iLS as revealed with the piscine urotensin
I antiserum may actually be Ucn III. Recently, Ucn III-
ir fibers were indeed found in this region of the LS (and
in the VMH), which corresponds well with the sites of
CRHR2 mRNA expression (P. E. Sawchenko, personal
communication).
CRHR1 and CRHR2 in anxiety, 
sleep/electroencephalographic regulation 
and HPA axis control: significance for clinical 
anxiety and depression
In recent years, many studies have been performed to
delineate the specific role of CRHR1 and CRHR2 in
stress-related physiological and behavioral processes to
gain insight into anxiety and major depressive disorders.
Various strategies have been employed including phar-
macological approaches, mutant mice with functional
deletions in one of the receptors, and antisense
oligodeoxynucleotide (ODN) technology.These inves-
tigations have provided insight into the complexity of
the contributions of CRHR1 and CRHR2 in the regu-
lation of emotional behavior, HPA axis activity, and
autonomic function. For some processes, the roles of
CRHR1 and CRHR2 seem clear, whereas for others
they still need to be clarified.
Anxiety
CRH is highly implicated in the regulation of anxiety-
related behavior and is thought to play a pivotal role in
anxiety and depressive disorders.
24,30,31 Several lines of
evidence point to the participation of CRHR1 in the
effects of CRH. First, CRHR1 binds CRH with high
affinity, in contrast to CRHR2. Second, CRHR1-defi-
cient mice show decreased anxiety-related behavior.
32,33
Third, transgenic mice overexpressing CRH show
increased anxiety-related behavior
34 (van Gaalen et al,
unpublished data). Fourth, central administration of
CRHR1 antisense ODNs inhibit CRH- and social
defeat–elicited anxiety-related behaviors and evoke
anxiolytic-like effects in certain anxiety tests, whereas
CRHR2 antisense ODNs did not produce any signifi-
cant effects in these tests.
35-38 Fifth, the selective (non-
peptidergic) CRHR1 antagonists (Figure 2),NBI-27914,
CRA1000, CRA1001 (all anilinopyrimidines), and
CP154526 (a pyrrolopyrimidine) inhibit the anxiogenic
action of CRH
39,40 (for review, see reference 41). How-
ever,it should be noted that,in many cases,the antago-
nists had no anxiolytic effect under nonstressed condi-
tions in behavioral paradigms such as the light/dark box
or elevated plus-maze, but did so after the animals had
been preexposed to stress.
39,40,42 Thus, it seems that the
antagonists need the release of endogenous CRH or
CRH-like peptide for their action to come about, also
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underlining that these compounds do not have any
intrinsic (cf, reverse agonist) activity.Anxiolytic effects
have also been observed with the more novel antago-
nists, R121919 (formerly called NBI-30775, a
phenylpyrimidine),
42,43 antalarmin (a pyrrolopyrimidine
derivative),
44,45 DMP904 (a pyrazolopyrimidine), and
DMP696 (a pyrazolotriazine).
46-48 Due to recent achieve-
ments in the development of nonpeptidergic CRHR1
ligands for single photon emission computed tomogra-
phy (SPECT) and positron emission tomography
(PET),in vivo monitoring of CRHR1 in the living brain
may soon become possible.
49,50
In summary, there is robust evidence that CRHR1 is
highly involved in anxiety-related behavior. Neverthe-
less, a role of CRHR2 in this cannot be excluded.The
three lines of CRHR2-deficient mice,
51-53 unfortunately,
do not provide an unambiguous answer to the question
about the role of this receptor in anxiety.In two lines of
CRHR2-deficient mice, increased anxiety-related
behavior was observed,
52,53 whereas in the third no
changes were found.
51 This disparity may be caused by
differences in genetic background, environmental fac-
tors,and the behavioral test conditions used.
54
Recent pharmacological experiments,however,point to
a much more complex involvement of CRHR2 in anxi-
ety.The picture is emerging that CRHR2 activation can
result in anxiolysis or anxiogenesis depending on the
timing of the animal test and, possibly, the localization
of the receptor.Radulovic et al
55 found that injection of
a high (500 ng/mouse) CRHR2-binding dose of h/rCRH
into the iLS of mice increases anxiety-like behavior in
the plus-maze 30 min postinjection,which was prevent-
ed by pretreatment with the CRHR2 antagonist anti-
sauvagine-30. Increased anxiety in the plus-maze was
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Figure 2. Chemical structures of several nonpeptidergic corticotropin-releasing hormone receptor type 1 (CRHR1) antagonists.
CP154526 Antalarmin
X = CH3S: CRA1000
X = Br: CRA1001 DMP696
NBI30545also observed 30 min after a 60-min immobilization trial,
which was prevented by intraseptal,but not intradorso-
hippocampal,administration of antisauvagine-30 before
the stress procedure.
55 Thus, acutely CRHR2-mediated
signaling in the iLS results in anxiogenesis. Physiologi-
cally, the CRHR2 in this nucleus is activated by Ucn
stemming from the EW,
20 and,likely more so,by Ucn III
from the perifornical region (P.E.Sawchenko,personal
communication).
14 In contrast, ICV administration of
the selective CRHR2 agonists mUcn II
56 or mUcn III
(E. Zorrilla, personal communication) results in
decreased anxiety-related behavior in the plus-maze not
acutely, but after 4 hours.Thus, CRHR2 in the brain is
capable of decreasing anxiety in a delayed fashion.
Thus, the anxiogenic and anxiolytic properties of
CRHR2 are certainly not paradoxical, because they
operate in different time domains poststress.Together,
it may be hypothesized that during the acute phase of
the stress response, the increase in emotionality is
evoked by CRH-mediated CRHR1 activation and Ucn-
or Ucn III–mediated CRHR2 activation,presumably in
the amygdala,BNST,and/or iLS.However,as part of the
recovery phase, CRHR2, following activation by Ucn,
Ucn II, and/or Ucn III, participates in reducing emo-
tionality some hours after the stressful experience.Thus,
CRHR2 mediates a dual mode of action on anxiety-
related behavior.A challenge for the future will be to
resolve the exact neural circuitry involved,the underly-
ing molecular and cellular mechanisms,and the manner
in which this dual action program is tuned by afferent
neural (eg,from the frontal cortex,hippocampus,hypo-
thalamus,and autonomic centers) and humoral (eg,glu-
cocorticoid hormones) input.
Sleep/electroencephalographic regulation
Sleep disturbances are often seen after exposure to
stress
57,58 and are also commonly observed in major
depressive disorders.
59 The disturbances observed in
depressed patients include a disinhibition of rapid eye
movement (REM) sleep (encompassing reduced REM
latency,reduced REM density,and prolonged first REM
sleep period), decreases in slow-wave-sleep (SWS),
increases in wakefulness, and disturbed sleep continu-
ity.
59 Evidence is accumulating that the sleep distur-
bances seen in depressed patients are at least in part due
to a hypersecretion of CRH or CRH-like peptides in the
CNS.Administration of CRH to rats or humans increas-
es wakefulness and decreases SWS,
60-62 whereas, con-
versely,ICV application of α-helical CRH(9-41) (a pep-
tidergic, predominantly CRHR1, antagonist) to rats
decreases wakefulness and increases SWS.
57 Moreover,
pretreatment with α-helical CRH(9-41) abolished the
stress-induced increases in REM sleep in rats.
58
Recently performed basic and clinical studies using
R121919 have provided further insight into the role of
CRHR1 in sleep/electronencephalographic (EEG) reg-
ulation and sleep disturbances in depressed patients.In
rats selectively bred for increased innate anxiety,
R121919 abolished the increases in plasma ACTH and
corticosterone levels and the decreases in sleep induced
by the administration of the vehicle (a citrate buffer,pH
4.8, an acid vehicle causing mild pain) (M. Lancel et al,
unpublished data).
63This observation points to a role of
CRHR1 in stress-induced changes in sleep.In depressed
patients treated for a time period of 30 days with
R121919,increases in SWS and decreases in the number
of awakenings and REM density were found.
64 By the
end of the treatment, an inverse correlation was found
between the duration of SWS and the severity level of
the depression (expressed as the Hamilton score).
64
However, plasma levels of cortisol (which is known to
affect sleep architecture) were hardly changed during
the course of treatment (H.E.Künzel et al,unpublished
data).These findings strongly suggest an involvement of
CRHR1 in the sleep disturbances seen in major depres-
sive disorders. Moreover, the sleep and endocrine data
together suggest that the hypersecretion of cortisol does
not have a major impact on sleep in depressed patients.
Currently, no information is available on the role of
CRHR2 in sleep regulation.Recently,the effects of ICV
administered urocortin on the EEG and on event-relat-
ed potentials (ERPs) of awake rats was evaluated.
65 It
was observed that the neuropeptide enhances arousal,
as determined by EEG, and modulates the speed of
stimulus evaluation as measured by ERPs.
65 Clearly,
insight into the function of CRHR2 in sleep/EEG regu-
lation awaits further investigations.
HPA axis control
Evidence has been accumulating that disturbances in
the regulatory control of the HPA axis play a pivotal
role in the etiology of major depression.
66,67 Moreover,
studies on depressed patients have indicated that there
appears to be a close correlation between a stable remis-
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37sion of the clinical symptomatology and a normalization
of HPA regulation.
68 The cause for the aberrant—in
most cases, hyperactive—HPA axis is presumably a
hyperactive central CRH system (for review, see refer-
ences 24, 30, and 69 to 71) and defunct brain and pitu-
itary corticosteroid receptor systems.
66,72,73 Although it
was more than a decade ago that a reduced CRH recep-
tor density was found in the frontal cortex of depressed
patients who had committed suicide,
3 efforts have only
recently started to delineate CRHR1 and CRHR2
expression in postmortem brains of depressed patients.
In a recent study,investigators observed in pituitaries of
suicide victims a shift in the ratio of CRHR1
(less)/CRHR2 (more) mRNA levels, but it was unclear
whether the victims had a history of major depressive
illness.
74 Studies on the role of CRHR1 and CRHR2 in
HPA regulation have mainly been performed in
rodents.
Recent studies on CRHR1- and CRHR2-deficient mice
indicate that these receptors play different roles in the
HPA axis. CRHR1-deficient mice are unable to mount
a stress-induced HPA response in terms of circulating
ACTH and corticosterone,whereas baseline ACTH lev-
els are normal and baseline corticosterone levels virtu-
ally undetectable.
32,33,75,76 Thus, CRHR1 is crucial for
stress-induced HPA responsiveness, but not for the
baseline hypothalamic-pituitary drive. For the latter,
vasopressin seems to be necessary and its expression
was even found to be increased in the PVH of CRHR1
mutants.
76 The observation that baseline corticosterone
levels were undetectable throughout the circadian cycle
revealed a role of CRHR1 in the development of the
adrenal medulla and adrenocortical sensitivity to
ACTH.
32 In the PVH,only low levels of CRHR1 mRNA
can be found, but levels are induced in response to
stress
22,77-80 or ICV CRH administration.
81This induction
of CRHR1 mRNA may be implemented in the positive
feedback action of CRH on paraventricular neurons,
but the evidence needs to be further solidified.
Exposure of the CRHR2-deficient and wildtype mice
to restraint stress revealed changes in HPA axis regu-
lation at different levels in two out of three mutant
lines.
51-53 Presumably, due to single-time-point analysis,
Kishimoto et al
53 did not observe any changes in stress-
induced HPA activity.The other two CRHR2 mutant
mouse lines showed increased responses in plasma
ACTH and corticosterone levels to restraint stress.
51,52
The plasma ACTH levels in the mutant mice decreased
within just 10 min of onset of stress, which is in sharp
contrast to the wildtype animals, whereas corticos-
terone levels continued to rise reaching higher levels
than the wildtypes.
51,52 At 90 min poststress, corticos-
terone levels were still higher in the mutant mice. It is
clear from these data that there is an array of changes
in the HPA axis of CRHR2 mutant mice that may
explain the different hormonal responses:(i) hypersen-
sitivity of the corticotrophs to hypothalamic secreta-
gogues; (ii) higher glucocorticoid levels cause ACTH
levels to fall earlier due to higher negative feedback
inhibition; and (iii) the adrenal cortex of the mutant
mice is possibly hypersensitive to ACTH.
51,52 In summa-
ry, these changes in HPA responses to stress suggest
that CRHR1 and CRHR2 are acting in an antagonistic
manner with CRHR1 acting proactively and CRHR2
acting attenuatively. The sites of these antagonistic
actions are currently unknown, but may include the
pituitary gland,the PVH,brain areas providing afferent
input to the PVH such as the amygdala,BNST,and the
lateral septum, and the sympathetic motor nuclei dri-
ving the sympathoadrenomedullary pathway. Studies
on the HPA axis of recently created CRHR1- and
CRHR2-double mutant mice confirm the data
obtained with the single gene mutants, with the
CRHR1 mutation nevertheless having a dominating
influence, presumably due to its “key” position on the
anterior pituitary corticotrophs.
82
Beside the CRH receptors,corticosteroid receptors are
also key elements in the regulation of the HPA axis.
72,73
They can be distinguished in two types of glucocorti-
coid-binding receptors: the mineralocorticoid receptor
(MR or type I) and the glucocorticoid receptor (GR or
type II).
83 MRs are mainly localized in the hippocampus,
whereas GRs have a widespread distribution in the
CNS.They have different functions in HPA regulation
with MRs mediating the tonic inhibitory influence of
the hippocampus (via the BNST) on parvicellular PVH
neurons and GRs mediating the negative feedback
action of glucocorticoids on HPA activity.
72,73,83 Recently,
we discovered a new mechanism of cross-talk between
the CRH neuropeptide systems and the hippocampal
MR.It was found that,within 8 h poststress,acute stres-
sors via a CRHR-mediated action cause an elevation in
MR levels in the hippocampus, which was associated
with an augmented MR-mediated inhibition of HPA
activity (Figure 3).
84 Thus, CRHRs are involved in
strengthening an important control instrument (ie,MR)
Basic research
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Figure 3. Effect of forced swimming stress on rat hippocampal mineralocorticoid (MR) receptor levels and its consequences for MR-mediated hypo-
thalamic-pituitary-adrenocortical (HPA) axis regulation. A. Within 24 h, forced swimming induces an increase in MR immunoreactivity in nuclei
of pyramidal and granular neurons in the CA1, CA2, and CA3 fields of the Ammon horn (not shown) hippocampal pyramidal layers and den-
tate gyrus (DG). This effect was stressor-specific, as it was also seen after novelty stress, but not after exposure to a cold environment (not
shown). B. Intracerebroventricular (ICV) pretreatment with the nonselective corticotropin-releasing hormone receptor (CRHR) antagonist 
D-Phe
12,Nle
21,38,α-Me-Leu
37)-CRH12-41 (D-Phe-CRH12-41) prevented the forced swimming–induced increase in hippocampal MRs. Moreover, 
ICV corticotropin-releasing hormone (CRH) treatment mimics the effect of stress on hippocampal MR levels (not shown). C. As shown in an 
RU 28318 challenge test, the forced swimming–induced elevation in hippocampal MR levels is associated with a potentiated MR-mediated
inhibition of HPA activity. RU 28318 is a selective MR antagonist and, after ICV administration and by blocking the MR, induces a release of
the HPA axis from the tonic inhibitory control elicited by hippocampal MRs. The experiment was based on the idea that, when MRs are upreg-
ulated poststress, the release of HPA activity by RU 28362 would be exaggerated compared with the control, unstressed, situation. Thus, rats
were stressed by forced swimming and 24 h later injected ICV with RU 28362. Trunk blood was collected 30 min postinjection. Indeed, the
results show that the release of HPA activity in terms of plasma corticosterone levels was larger when rats had been stressed 24 h earlier, indi-
cating that the stress-induced increase in hippocampal MR levels is associated with an enhanced MR-mediated tonic inhibitory control of HPA
axis activity. For further details, see reference 84. 
Reproduced from reference 84: Gesing A, Bilang-Bleuel A, Droste SK, Linthorst ACE, Holsboer F, Reul JMHM. Psychological stress increases hippocampal miner-
alocorticoid receptor levels: involvement of corticotropin-releasing hormone. J Neurosci. 2001;21:4822-4829. Copyright © 2001, Society for Neuroscience.of the HPA axis.Although the effect of stress was mim-
icked by an ICV injection of CRH, pointing to an
involvement of CRHR1 (Figure 3),
84 exactly which
CRH receptor—CRHR1 or CRHR2—is the mediator
of this phenomenon needs to be clarified, as much as
the localization of these receptors. Furthermore, we
have postulated that, given the eminent role of the
CRH-MR pathway in maintaining control of HPA axis
activity poststress, in patients suffering from a stress-
related disorder,such as major depression,HPA hyper-
activity may have developed due to desensitization of
MR-inducibility by CRH or CRH-like neuropep-
tides.
73,84
To summarize,CRHR1 plays a critical role in the acute
phase of the stress-induced HPA response, whereas
CRHR2 is involved in the recovery phase.The stress-
evoked increase in hippocampal MR expression
appears to be part of the recovery phase, but whether
this element is mediated by CRHR1 or CRHR2 needs
clarification.
Significance for anxiety disorders and depression
A CRH hyperfunction in the brain appears to be a char-
acteristic often seen in major depression and anxiety
disorders.This notion originates from cerebrospinal
fluid (CSF) CRH measurements, CRH binding, and
CRH challenge tests.
4,85 Comparison of a variety of stud-
ies on CSF CRH measurements revealed that this was
not an equivocal finding in all studies, but seemed to
depend on certain factors associated with depressive ill-
ness. It is especially those patients showing melancho-
lia, psychosis, hypercortisolemia, and dexamethasone
nonsuppression who present elevated CSF CRH levels
(for reviews, see references 69 and 70). It is presently
still unclear where in the brain the elevated levels of
CRH in the CSF stem from.It is,however,unlikely that
they are derived exclusively from the PVH.The hyper-
secreted CRH may originate from the central amyg-
daloid nucleus,in which the neuropeptide’s synthesis is
known to be under positive control by glucocorticoid
Basic research
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86 Thus, those depressed patients who hyper-
secrete glucocorticoids—at least in part due to defunct
hippocampal inhibition of HPA activity (see above and
Figure 4)— also have increased CRH synthesis in the
central amygdaloid nucleus. Indeed, hypercortisolemia
in depressed patients is associated with elevated CSF
CRH levels (see above).The increased expression of
CRH in the central amygdaloid nucleus may be respon-
sible for the increase in emotionality and anxiety, and
the neurovegetative instability often associated with
major depression.
87,88 Moreover,the central amygdaloid
nucleus exerts a stimulatory influence on the HPA axis,
via its direct and indirect (via the BNST) connections to
the PVN.
73 It may be speculated that in depressed
patients a positive feed-forward loop may have been
established between the amygdala and the HPA axis.
Given that the neural and humoral components of this
loop have uncountable interactions with other—central
and peripheral—systems,the consequences will be man-
ifold, including effects on mood, cognition, libido, the
cardiovascular system,immune system,and metabolism
(Figure 4).
Above, we postulated that CRHR1 and CRHR2 play
different roles in stress-evoked anxiety, in which both
receptors operate, possibly in different regions of the
brain (eg, central amygdaloid nucleus, BNST, interme-
diate LS), in the acute (anxiogenic) phase of the stress
response, and in which CRHR2 promotes anxiolysis
during the stress recovery phase. We have also
described a parallel mechanism for the role of these
receptors in the stress-induced HPA response.As men-
tioned, there are strong indications for a CRH-evoked
CRHR1-mediated hypersignaling in the brain of
patients suffering from anxiety and depressive disor-
ders.This condition is thought to be responsible for the
increases in emotionality and HPA activity, and neu-
rovegetative and sleep disturbances seen in these
patients. Indeed, a preliminary exploratory clinical
study in our clinical department at the Max Planck
Institute of Psychiatry in which depressed patients were
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Figure 4. Shift in limbic afferent control of the hypothalamic-pituitary-adrenocortical (HPA) axis and its consequences for affective states and physio-
logical functioning. This figure presents a working hypothesis on limbic-HPA axis interactions in anxiety and depressive disorders. On the basis
of established afferent and efferent regulatory interactions between the HPA axis and its limbic “partners” (the hippocampus and the amyg-
dala), we propose a framework giving a neuropharmacological basis to the psychiatric, neurovegetative, and physiological disturbances seen
in anxiety and depressive disorders. Patients suffering from major depression or pathological anxiety often show a dysregulated—mostly hyper-
active—HPA axis which is associated with increased cerebrospinal fluid (CSF) levels of corticotropin-releasing hormone (CRH).
30,69,70 Apart from
intrinsic HPA axis disturbances at the hypothalamic, pituitary, or adrenal level, the reason for the HPA hyperactivity may well derive from defunct
processes in the hippocampus and central amygdaloid nucleus (CeA) known to provide direct and indirect efferent projections to the hypo-
thalamic paraventricular nucleus (PVH).
73,89 As postulated (see text), chronic stressful life events result in a loss of capacity of CRH or CRH-relat-
ed peptides to upregulate hippocampal mineralocorticoid receptor (MR) levels (1) leading to a loosening of the tonic inhibitory influence on
parvicellular neurons in the PVH.
73 In depressed patients and in a variety of animal models, a reduced expression of MR has indeed been
found.
72,73,90 (2) Consequently, levels of CRH and coexpressed vasopressin will increase in these neurons (for a review, see references 65, 72,
and 74) providing an enhanced drive on HPA activity, anterior pituitary (APit) CRH-binding receptor (CRHR1) desensitization, and adrenal hyper-
plasia.
66,73 (3) Subsequently, the elevated circulating glucocorticoid levels will raise CRH expression in the CeA,87 (4) resulting in an enhanced
stimulatory influence on the PVH. In this manner, a positive feed-forward loop develops accelerating the establishment of a state of sustained
HPA hyperactivity. Importantly, regarding the activity of the efferent amygdaloid and hippocampal projections to the nucleus accumbens, (5)
a shift may occur toward an augmented input from the CeA relative to that from the hippocampus. Such a shift will result in an increased
emotionality likely to develop in vulnerable subjects to pathological anxiety and mood disorders. Finally, the enhanced—caudally directed—
CeA activity leading to an increased sympathetic outflow in combination with the excess glucocorticoid levels can result in a variety of neu-
rovegetative (eg, cardiovascular or gastrointestinal problems), metabolic, and immune disturbances, often seen in anxiety, mood, and psy-
chosomatic disorders. Also, CeA- and hippocampus-associated structures are drawn such as the cortical nucleus amygdala (CoA), basolateral
amygdala (BLA), and medial nucleus amygdala (MA) with regard to the CeA, and the lateral septum (LS) and medial septum (MS) with regard
to the hippocampus because they participate strongly in CeA and hippocampus functioning. In addition, their own function is modulated by
incoming signals via CRHR1 and/or CRHR2. The bed nucleus stria terminalis (BNST), containing both CRHR1 and CRHR2, is drawn because it
is an important relay station for hippocampal output to the PVH. Thus, this model can be used as a framework to investigate in an integra-
tive manner the anxiogenic, anxiolytic, HPA-driving, HPA-restraining, and other actions of CRH, urocortin (Ucn), Ucn II, and Ucn III. Such stud-
ies should also implement interactions of these neuropeptides with the classic neurotransmitters, which, for sake of clarity, were not depict-
ed in the scheme, as were other, possibly participating, structures such as, for instance, the thalamic paraventricular nucleus which contains
low-to-moderate CRHR1 levels.
22,91 The elucidation of the interactions between the various components of this network including the CRHRs
and their ligands will bring forward new pharmacotherapeutic strategies for the treatment of anxiety and depressive disorders.
Note: The green boxes comprise primary elements (ie, brain regions and parts of the HPA axis) of the system of limbic-HPA axis interactions.
The orange ovals represent the different categories of pathological disturbances resulting (as indicated by the pointing hands) from aberrant
functioning of certain elements of the network. The localization in certain elements (eg, brain regions, APit, adrenal gland) of CRHR1 is indi-
cated in red, CRHR2 in blue, whereas other important components such as CRH, adrenocorticotropic hormone (ACTH), glucocorticoids, and
MR, are indicated in dark green. With (1) to (5) the sequence of the progressive disturbances are denoted (see main text of legend). CRHR1i:
CRHR1 mRNA inducible by stress or CRH (see text).treated with the nonpeptidergic CRHR1 antagonist
R121919 showed that blocking CRHR1 signaling in
these patients had beneficial effects (Figure 5). Beside
the effects on sleep architecture (see above),
64 the treat-
ment resulted in a substantial reduction in the depres-
sion (Figure 5) and anxiety scores.
92The current status of
research promises that CRHR1 antagonism represents
a novel pharmacotherapeutic strategy to treat depres-
sion, pathological anxiety such as phobias, panic, and
posttraumatic stress disorder.This new development in
the pharmacological treatment of major depressive and
anxiety disorders is a significant step toward the forma-
tion of basic science-driven therapies.It is to be expect-
ed that this development is also an important step on
the way to the ultimate goal of a pharmacotherapy with
rapid onset of clinical effect,negligible side effects,and
absent treatment resistance.
Nevertheless,extrapolating the aforementioned hypoth-
esis, it cannot be excluded that, apart from CRHR1
hyperfunction, a condition of CRHR2 hypofunction
may exist in depressed patients. Due to impaired
CRHR2-mediated anxiolysis, the subject might remain
in an extended state of anxiety and arousal. Possibly,
other stress recovery processes could also be impaired
by the defunct CRHR2, including HPA regulation and
autonomic processes.
17,51-53,93,94
Figure 4 present a working hypothesis based on an inte-
gration of the previously described issues. Our hypo-
thetical model basically proposes a mechanism in which
the development of anxiety and mood disorders is
caused by a shift in the balance between the effects of
the hippocampus and the central amygdaloid nucleus
initially on the HPA axis, but eventually also on the
nucleus accumbens and frontal cortex, brain regions
involved in the regulation of affective states.The altered
state of amygdaloid output is also expected to affect
autonomic outflow which, in combination with the
enhanced glucocorticoid secretion,could be responsible
Basic research
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Figure 5. Changes in the self-rating Beck Depression Inventory (BDI; left) and the 21-item Hamilton Depression Rating Scale (HAMD; right) during and
after treatment with the nonpeptidergic CRHR1 antagonist R121919 (formerly called NBI-30775) and the selective serotonin reuptake inhibitor
(SSRI) paroxetine. During the screening period, all psychoactive medication was stopped for a minimum of 5 days. Patients were enrolled in
two dose escalation panels. In panel 1, the dose range increased from 5 to 40 mg (open diamonds), whereas, in panel 2, the dose range
increased from 40 to 80 mg (closed circles). The increases took place within 30 days. The panel 2 treatment regimen resulted in a response
rate (ie, 50% reduction of the initial severity of depression) equivalent to that found in paroxetine-treated patients (open squares; historical
data for patients matched according to age, gender, and severity of depression; patients had been treated with 20 to 40 mg paroxetine under
clinical drug study conditions). In both panels, HAMD and BDI rating scales worsened after discontinuation of R121919. Data are means ±
standard error of the mean. 
Reproduced from reference 92: Zobel AW, Nickel T, Künzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor I antagonist R121919
in major depression: the first 20 patients treated. J Psychiatr Res. 2000;34:171-181. Copyright © 2000, Elsevier Science.for the physiological, metabolic, and immune distur-
bances often seen in depressed and anxious patients.
The CRH neuropeptide family and their receptors are
major participants in this network and, with the recent
growth of this family (ie, Ucn II and Ucn III), a major
step has been made toward the elucidation of the roles
of CRHR1 and CRHR2 in anxiety and depression.
Concluding remarks
Overall,the pattern that is emerging is one of a network
subserving the acute and the recovery phase of the
stress-coping response. Recent advances with regard to
the growth of the CRH neuropeptide family, the dual
function of CRHR1 and CRHR2 in anxiety and HPA
regulation, and the CRH-MR regulatory shunt in HPA
axis control have provided the cornerstones for a signif-
icant leap in our understanding of the wiring and timing
of the stress-coping response. Of utmost importance
here is the acquired knowledge about the stress defense
mechanisms underpinning anxiolysis,HPA control,and
autonomic stability.These advances open the way for
the development of novel classes of antidepressant
drugs not just targeting the acute response systems, but
also acting as supports to the stress defense mechanisms.
To  address this goal, substantial investments are
required to further elucidate the regulatory pathways
and players governing the network both in health and
disease. In view of the recent development in the fields
of functional and pharmacogenomics (for instance, see
reference 95),and proteomics,together with the experi-
ence of several decades of research in stress physiology,
pharmacology, neuroanatomy, and molecular biology,
this challenge can be surmounted.❏
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El papel de los receptores de la hormona
liberadora de corticotropina en la ansiedad
y en la depresión
En base a numerosos estudios clínicos y básicos se
considera que la hormona liberadora de cortico-
tropina (CRH) y las sustancias de la misma familia
juegan un papel central en los trastornos rela-
cionados con el estrés, como la ansiedad y la
depresión. La CRH es considerada el mediador
principal en el cerebro de la respuesta de estrés,
ya que media las respuestas neuroendocrinas,
autonómicas y conductuales a los estímulos estre-
santes. Recientemente esta familia de neuropép-
tidos se ha incrementado debido al descubri-
miento de dos nuevos miembros, la urocortina II
(también denominada “stresscopin-related pep-
tide”) y la urocortina III (también llamada “stress-
copin”), las cuales son agonistas selectivos de los
receptores de CRH tipo 2. Ellas muestran una
localización anatómica reducida y participan en
las respuestas de adaptación al estrés como la
ansiolisis. Según esto, en base a descubrimientos
recientes, nosotros sugerimos que la CRH, las uro-
cortinas y sus receptores forman un sistema com-
plejo en el cerebro, el cual interviene tanto en la
fase aguda como en la fase de recuperación de la
respuesta de estrés.
Rôle des récepteurs de la corticolibérine
sur l’anxiété et la dépression 
De grandes études cliniques ont montré que la
corticolibérine (CRH) et les substances de la même
famille jouent un rôle central dans les troubles
liés au stress tels que l’anxiété et la dépression. La
CRH est considérée comme le principal média-
teur cérébral de réponse au stress, en particulier
pour ce qui concerne les réponses neuroendocri-
niennes, autonomes et comportementales aux
situations de stress. Récemment, cette famille de
neuropeptides s’est agrandie grâce à la décou-
verte de deux molécules agonistes sélectifs du
récepteur de la CRH de type 2, l’urocortine II et
l’urocortine III (désignées par nous respective-
ment sous les termes de « stresscopin-related
peptide » et « stresscopin »). Ces molécules mani-
festent une discrète localisation neuroanato-
mique et sont impliquées dans les réponses
d'adaptation au stress telles que l'anxiolyse. Sur la
base de découvertes récentes, nous avançons l’hy-
pothèse que la CRH, les urocortines et leurs
récepteurs forment, dans le cerveau, un système
complexe qui entre en jeu tant dans les phases
aiguës que lors des phases de récupération de la
réponse au stress. REFERENCES
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